JP2019014684A - 真菌感染における宿主応答抑制剤 - Google Patents
真菌感染における宿主応答抑制剤 Download PDFInfo
- Publication number
- JP2019014684A JP2019014684A JP2017134071A JP2017134071A JP2019014684A JP 2019014684 A JP2019014684 A JP 2019014684A JP 2017134071 A JP2017134071 A JP 2017134071A JP 2017134071 A JP2017134071 A JP 2017134071A JP 2019014684 A JP2019014684 A JP 2019014684A
- Authority
- JP
- Japan
- Prior art keywords
- vnut
- compound
- group
- atp
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017134071A JP2019014684A (ja) | 2017-07-07 | 2017-07-07 | 真菌感染における宿主応答抑制剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017134071A JP2019014684A (ja) | 2017-07-07 | 2017-07-07 | 真菌感染における宿主応答抑制剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019014684A true JP2019014684A (ja) | 2019-01-31 |
| JP2019014684A5 JP2019014684A5 (enExample) | 2020-08-27 |
Family
ID=65356397
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017134071A Pending JP2019014684A (ja) | 2017-07-07 | 2017-07-07 | 真菌感染における宿主応答抑制剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2019014684A (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024225368A1 (ja) | 2023-04-28 | 2024-10-31 | 学校法人 久留米大学 | アデノシン三リン酸分泌抑制剤、肝星細胞活性化抑制剤、肝星細胞脱活性化剤、肝線維症治療剤、非アルコール性脂肪性肝炎治療剤、乾癬治療剤並びにアデノシン三リン酸分泌抑制剤、肝星細胞活性化抑制剤、肝星細胞脱活性化剤、肝線維症治療剤、非アルコール性脂肪性肝炎治療剤及び乾癬治療剤の製造のための化合物の使用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001131073A (ja) * | 1999-11-09 | 2001-05-15 | Sumitomo Pharmaceut Co Ltd | 疼痛治療剤 |
| US20050152905A1 (en) * | 2002-08-22 | 2005-07-14 | Omoigui Osemwota S. | Method of biochemical treatment of persistent pain |
| WO2005072746A1 (ja) * | 2004-01-30 | 2005-08-11 | Astellas Pharma Inc. | P2x受容体阻害剤 |
| WO2009116546A1 (ja) * | 2008-03-18 | 2009-09-24 | 国立大学法人 岡山大学 | 興奮性化学伝達調節剤およびそのスクリーニング法 |
-
2017
- 2017-07-07 JP JP2017134071A patent/JP2019014684A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001131073A (ja) * | 1999-11-09 | 2001-05-15 | Sumitomo Pharmaceut Co Ltd | 疼痛治療剤 |
| US20050152905A1 (en) * | 2002-08-22 | 2005-07-14 | Omoigui Osemwota S. | Method of biochemical treatment of persistent pain |
| WO2005072746A1 (ja) * | 2004-01-30 | 2005-08-11 | Astellas Pharma Inc. | P2x受容体阻害剤 |
| WO2009116546A1 (ja) * | 2008-03-18 | 2009-09-24 | 国立大学法人 岡山大学 | 興奮性化学伝達調節剤およびそのスクリーニング法 |
Non-Patent Citations (8)
| Title |
|---|
| BIOL. PHARM. BULL., vol. 39, JPN6022010429, 2016, pages 770 - 777, ISSN: 0004729001 * |
| EUROPEAN JOURNAL OF PAIN, vol. 12, JPN6022010427, 2008, pages 284 - 292, ISSN: 0004729000 * |
| EXPERIMENTAL NEUROLOGY, vol. 254, JPN6021024946, 2014, pages 41 - 53, ISSN: 0004729003 * |
| JPN. J. MED. MYCOL., vol. 44, JPN6021024944, 2003, pages 193 - 196, ISSN: 0004728998 * |
| NEUROCHEMISTRY INTERNATIONAL, vol. 99, JPN6021024949, 2016, pages 85 - 93, ISSN: 0004729005 * |
| NEUROPHARMACOLOGY, vol. 47, JPN6021024948, 2004, pages 286 - 294, ISSN: 0004729004 * |
| SCI. TRANSL. MED., vol. Vol. 3, Issue 101, JPN6021024945, 2011, pages 101 - 91, ISSN: 0004728999 * |
| ソルト・サイエンス研究財団助成研究報告書2 医学 食品科学編, vol. 2015, JPN6021024943, March 2017 (2017-03-01), pages 221 - 226, ISSN: 0004729002 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024225368A1 (ja) | 2023-04-28 | 2024-10-31 | 学校法人 久留米大学 | アデノシン三リン酸分泌抑制剤、肝星細胞活性化抑制剤、肝星細胞脱活性化剤、肝線維症治療剤、非アルコール性脂肪性肝炎治療剤、乾癬治療剤並びにアデノシン三リン酸分泌抑制剤、肝星細胞活性化抑制剤、肝星細胞脱活性化剤、肝線維症治療剤、非アルコール性脂肪性肝炎治療剤及び乾癬治療剤の製造のための化合物の使用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11957931B2 (en) | Compositions and methods for treating vitiligo | |
| Marshall et al. | Angiotensin II and the fibroproliferative response to acute lung injury | |
| Zhou et al. | The role of autophagy in angiotensin II-induced pathological cardiac hypertrophy | |
| Lamming | Inhibition of the mechanistic target of rapamycin (mTOR)–rapamycin and beyond | |
| Bondaryk et al. | Antifungal agents commonly used in the superficial and mucosal candidiasis treatment: mode of action and resistance development | |
| Chen-Scarabelli et al. | The role and modulation of autophagy in experimental models of myocardial ischemia-reperfusion injury | |
| Long et al. | SGLT2 inhibitor, canagliflozin, ameliorates cardiac inflammation in experimental autoimmune myocarditis | |
| Palin et al. | Interleukin-6 activates arginine vasopressin neurons in the supraoptic nucleus during immune challenge in rats | |
| KR20200121780A (ko) | 높은 농도에서 핵산을 포함하는 제제 | |
| Zhang et al. | Minocycline promotes cardiomyocyte mitochondrial autophagy and cardiomyocyte autophagy to prevent sepsis-induced cardiac dysfunction by Akt/mTOR signaling | |
| Shan et al. | Protective effects of dimethyl itaconate in mice acute cardiotoxicity induced by doxorubicin | |
| Li et al. | AMPK activates FOXO3a and promotes neuronal apoptosis in the developing rat brain during the early phase after hypoxia-ischemia | |
| Gardner et al. | Phosphatase control of 4E-BP1 phosphorylation state is central for glycolytic regulation of retinal protein synthesis | |
| KR20050085966A (ko) | 레닌-안지오텐신계 억제제의 용도 | |
| Peng et al. | Effects of ghrelin on pulmonary NOD2 mRNA expression and NF-κB activation when protects against acute lung injury in rats challenged with cecal ligation and puncture | |
| JP2019511495A (ja) | GSK3β阻害薬チデグルシブによるCDKL5障害の治療 | |
| Mertes et al. | Liposomal encapsulation of trans-crocetin enhances oxygenation in patients with COVID-19-related ARDS receiving mechanical ventilation | |
| Wu et al. | Regulated cell death in hypoxic-ischaemic encephalopathy: recent development and mechanistic overview | |
| Ma et al. | Activated FMS‐like tyrosine kinase 3 ameliorates angiotensin II‐induced cardiac remodelling | |
| Gilbertie et al. | Oral reserpine administration in horses results in low plasma concentrations that alter platelet biology | |
| Chen et al. | Impaired expression of postsynaptic density proteins in the hippocampal CA1 region of rats following perinatal hypoxia | |
| Menegola et al. | Dysmorphogenic effects of some fungicides derived from the imidazole on rat embryos cultured in vitro | |
| Nieto et al. | Comparison of conventional and lipid emulsion formulations of amphotericin B: pharmacokinetics and toxicokinetics in dogs | |
| JP2019014684A (ja) | 真菌感染における宿主応答抑制剤 | |
| Thorsen et al. | BAY 41-2272 inhibits the development of chronic hypoxic pulmonary hypertension in rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200706 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200706 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20200706 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200706 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210629 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210825 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211021 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20211021 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220316 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220914 |